What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world

Drug Safety

Volumn 26, Issue 4, 2003, Pages 219-225

  Fernandopulle, Rohini B M ^a   Weerasuriya, Krisantha ^a  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MEFENAMIC ACID; PRASTERONE; SILDENAFIL;

CONSUMER; DATA BASE; DEVELOPING COUNTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL HEMORRHAGE; GOVERNMENT; HUMAN; LAW; MEDICAL INFORMATION SYSTEM; MEDICAL PROFESSION; MUSCLE NECROSIS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REGISTRATION; REVIEW; SELF REPORT; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; CONSUMER PARTICIPATION; DATABASES, FACTUAL; HEALTH OCCUPATIONS; HUMANS;

EID: 0037236314     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326040-00002     Document Type: Review

References (29)

1. The First International Conference on Consumer Reports 2000 Sigtuna. Consumer reporting of adverse drugs reactions. WHO Drug Information 2000; 14 (4): 211-5
2. Edwards IR, editor. Pharmacovigilance - beyond 2000: opinion and evidence drug safety 2nd ed. Auckland: Adis International Ltd, 2000
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients; a meta-analysis of prospective studies. JAMA 1998 Apr; 279 (15): 1200-5
4. Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999 May; 281 (18): 1728-34
5. Under reporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci 1999; 168 (4): 257-61
6. Backstrom M, Mjorndal T, Dahlqvist R, et al. Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol 2000 Dec; 56 (9-10): 729-32
7. Smith CC, Bennet PM, Pearce HM, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996 Oct; 42 (4): 423-9
8. Martin RM, Kapoor VK, Wilton LV, et al. Under-reporting of suspected adverse drug reactions to newly marketed (black triangle) drugs in general practice: observational study. BMJ 1998 Jul; 317: 119-20
9. Drug safety reporting in clinical trials. Reactions Weekly 2001; 851: 2-3
10. Uppsala Monitoring Centre. Reporting 2000 to the WHO programme. 2001. (Data on file)
11. Thomas M. Post-marketing surveillance problems and possible solutions in developing countries. Pharm Med 1993; 7: 267-71
12. Meyboom RHB, Egberts AGC, Edwards IR, et al. Principles of signal detection in Pharmacovigilance. Drug Saf 1997 Jun; 16 (6): 355-65
13. Gonzalez CH, Dias MMJ, Kim GA, et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998; 351: 1624-7
14. Wang PS, Bohn RI, Glynn RJ, et al. Hazardous benzodiazepine regimes in the elderly; effects of half life, dosage and duration on risk of hip fracture. Am J Psychiatry 2001; 158: 892-8
15. World Health Organisation Drug Information 2002; 16 (1): 8-11
16. Ministry of Health. Annual health bulletin 1998. Sri Lanka: Ministry of Health, 72
17. Hartingan-Go K. Pharmacovigilance and the pursuit of rational drug use: the Philippines experience. Uppsala Reports 2001 Suppl. 14 Apr 2001
18. Drug Evaluation subcommittee. Alert about intramuscular diclofenac. Sri Lanka: Prescriber, 1998: 6 (1) 6
19. Mansfield P. Adverse Drug reactions Reporting by patients [online]. Available from URL: http://www.healthnet.org/programs/e-drug 1998 [Accessed 2002 May 30]
20. Edwards IR. Who cares about pharmacovigilance? Eur J Clin Pharmacol 1997; 53: 83-8
21. Egberts TCG, Smulders M, de Koning FHP, et al. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996 Aug; 315: 530-1
22. Mitchell AS, Henry DA, Sanson-Fisher R, et al. Patients as a direct source of information on adverse drug reactions. BMJ 1988; 297: 891-3
23. Mitchell AS, Henry DA, Hennrikus D, et al. Adverse drug reactions: can consumers provide early warnings? Pharmacoepidemiol Drug Saf 1994; 3: 257-64
24. Alvarez RA, Cavajal A, Begaud B, et al. Under-reporting of adverse drug reactions, estimate based on a spontaneous reporting scheme and a sentinal system. Eur J Clin Pharmacol 1998 Aug; 54 (6): 483-8
25. Medawar C. The Antidepressant web. Int J Risk Safety Med 1997; 10: 75-126
26. Eisenberg DM, Kessler RD, Foster C, et al. Unconventional medicine in the United States: prevalence costs and patterns of use. N Engl J Med 1993; 328: 246-52
27. Meek C. Direct to consumer advertising (DTCA) of prescription medicines: first quarterly update. January to March 2002. DTCA Update Report, Quarter 1, 2002 [online]. Available from URL: www.rpsgb.org.uk/pdfs/dtcarev/0203.pdf [Accessed 2003 Feb 12]
28. Glass RM, Molter J, Hwang MY. Educating patients: one-year anniversary of the JAMA Patient Page [letter]. JAMA 1999 Apr; 281 (16): 1544
29. Woodcock J. Understanding adverse drug reactions and medication errors: a speech delivered to the US senate Health Education and labour committee [online]. Available from URL: http//www.alsna.com/mederrors.html [Accessed 2001 May 3]